



# The impact of the pandemic on mental health

The MHCOVID Project



SWISS NATIONAL SCIENCE FOUNDATION



**Covid-19**  
National Research Programme

# The mhccovid working group



**Georgia Salanti**

**Principal Investigator**

University of Bern, Switzerland



**Andrea Cipriani**

**Co-applicant**

University of Oxford, UK



**Nicola Low**

**Co-applicant**

University of Bern, Switzerland



**Thomy Tonia**

**Researcher**

University of Bern, Switzerland



**Alexander Holloway**

**Researcher**

University of Bern, Switzerland



**Stefan Leucht**

**Principal Investigator**

Technical University of Munich, Germany



**Toshi Furukawa**

**Co-applicant**

University of Kyoto, Japan



**Natalie Peter**

**Researcher**

Technical University of Munich, Germany



# MHCOVID STEERING COMMITTEE



**MHCOVID**

[About](#)

[People](#)

[Aim](#)

[Methods](#)

[Living Review](#) ▼



[Crowd](#)

## Steering committee

**Pim Cuijpers**, Vrije Universiteit Amsterdam, The Netherlands

**Matthias Egger**, University of Bern, Switzerland (Swiss COVID19 Task Force, Swiss National Science Foundation)

**Seena Fazel**, University of Oxford, UK

**Helen Herrman**, Orygen and The University of Melbourne, Australia

**Ronald Kessler**, Harvard Medical School, USA

**Christian Kieling**, Federal University of Rio Grande do Sul, Brazil

**Tianjing Li**, University of Colorado Anschutz Medical Campus, USA

**Chunbo Li**, Shanghai Jiao Tong University, China


**Vikram Patel**, Harvard Medical School, USA

**Dominique De Quervain**, University of Basel, Switzerland (Swiss COVID19 Task Force)

**Simone Vigod**, University of Toronto, Canada

**Ian White**, University College London, UK

# MHCOVID website <https://mhcovid.ispm.unibe.ch>



The screenshot shows the MHCOVID website homepage. At the top is a navigation bar with the MHCOVID logo and links for About, People, Aim, Methods, Living Review, and a Crowd icon. The main content area has a blue background with a world map and the title 'Mental Health COVID'. Below the title is a paragraph explaining the project's purpose. Further down is another paragraph detailing the methodology. At the bottom, three blue boxes display statistics: 43,261 papers identified, 39,983 papers screened, and 6,373 papers included. Below these are three icons: a group of people, a clipboard, and two people at a laptop.

**MHCOVID** About People Aim Methods Living Review ▾ Crowd

## Mental Health COVID

MHCOVID is a living online systematic review of scientific evidence about changes in the prevalence of mental health issues due to the COVID-19 pandemic and containment measures.

We take a **global view**, and seek to determine how the extent of containment measures are associated with mental health issues (including violent behaviour, and alcohol and substance abuse) in the general population, as well as various sub-populations. Our project makes use of **crowdsourcing** techniques to increase the quantity of evidence we can include in our analyses, and our results are continuously updated as more evidence becomes available.

**43,261 papers identified** **39,983 papers screened** **6,373 papers included**

Icons at the bottom: a group of people, a clipboard, and two people at a laptop.


# Questions that mhcovid aims to answer

- What is the prevalence of mental health problems (*including alcohol/drug abuse and violence*) in the **general population\*** and subpopulations worldwide during the COVID-19 pandemic?
- How are mental health problems associated with
  - a) characteristics of the pandemic
  - b) the extent and intensity of measures to contain the pandemic?
  - c) which population characteristics (e.g. sex, age, comorbidities) modify these prevalences.

\*not healthcare personnel, COVID19 patients etc

# Living online systematic review and meta-ecological study


**Outcome:**  
Mental health during the pandemic





# MHCOVID Crowd

114 researchers



# Our crowd: 66 trained extractors


with experience in mental health and/or systematic reviews

Abdulkadir	Usman Sambo	Federal Neuropsychiatric Hospital Kaduna, Nigeria
Akira	Onishi	Kobe University, Japan
Akira	Sato	Kyoto University, Japan
Alessandro	Rodolico	University of Catania, Italy
Ana Cristina	de Oliveira Solis	University of São Paulo Medical School, Brazil
Anastasia	Antoniou	National and Kapodistrian University of Athens, Greece
Angelika	Kapfhammer	Technical University of Munich, Germany
Anna	Ceraso	University of Brescia, Italy
Aoife	O'Mahony	Cardiff University, UK
Aran	Tajika	Kyoto University, Japan
Aurélie	Lasserre	Centre for Addiction and Mental Health, Canada
Aya	Suganuma	Kyoto University, Japan
Aziz Mert	Ipekci	University of Bern, Switzerland
Bawan	Ahmed	University of Greenwich, UK
Caidi	Zhang	Shanghai Jiao Tong University, China
Carmen	Concerto	University of Catania, Italy
Caroline	Zangani	University of Oxford, UK
Chinonso	Igwesi-Chidobe	University of Nigeria, Nigeria
Christina	Diehm	Marion von Tessin Memory Zentrum, Germany
Daniela	Parra	Universidad CES, Colombia
Dicle Dilay	Demir	Erenköy Mental Health and Neurological Diseases Hospital, Turkey
Dongfang	Wang	Technical University of Munich, Germany
Edoardo	Ostinelli	University of Oxford, UK
Ethan	Sahker	Kyoto University, Japan
Fidel	Vila-Rodriguez	University of British Columbia, Canada
Gabriel Henrique	Beraldi	University of São Paulo Medical School, Brazil
Gamze	Erzin	University of Maastricht, The Netherlands
Harrison	Nelson	Queen's University, Canada
Helio	Elkis	University of São Paulo Medical School, Brazil
Hissei	Imai	Kyoto University, Japan


Hui	Wu	Technical University of Munich, Germany
Ilias	Kamitsis	University of Melbourne, Australia
Ioannis	Filis	National and Kapodistrian University of Athens, Greece
Ioannis	Michopoulos	National and Kapodistrian University of Athens, Greece
Irene	Bighelli	Technical University of Munich, Germany
James Sang		
Woo	Hong	University of Oxford, UK
Javier	Ballesteros	University of the Basque Country, Spain
Johanna	Schneckenburger	kbo-Lech-Mangfall-Klinik Hausham, Germany
Katharine	Smith	University of Oxford, UK
Kazufumi	Yoshida	Kyoto University, Japan
Kenji	Omae	Fukushima Medical University, Japan
Laila	Asmal	Tygerberg Hospital, South Africa
Magdalini	Triantafyllidou	Hellenic Open University, Greece
Marialena	Trivella	University of Oxford, UK
Masafumi	Tada	Nagoya University, Japan
Matthias A	Reinhard	Ludwig-Maximilians-Universität Munich, Germany
Meenakshi	Sharma	Post Graduate Institute of Medical Education and Research, India
Michael	Ostacher	Stanford University, USA
Michael A	Wewege	University of New South Wales, Australia
Monika	Müller	King's College London, UK
Nathalia	Gonzalez Jaramillo	University of Bern, Switzerland
Nuoshi	Qian	Shanghai Jiao Tong University, China
Panagiotis	Ferentinos	National and Kapodistrian University of Athens, Greece
Rie	Toyomoto	Kyoto University, Japan
Samuele	Cortese	University of Southampton, UK
Sanae	Kishimoto	Kyoto University, Japan
Satsuki	Oe	Kyoto University, Japan
Sergio	Covarrubias-Castillo	Hospital Civil de Guadalajara, Mexico
Shino	Kikuchi	Kyoto University, Japan
Spyridon	Siafis	Technical University of Munich, Germany
Stephanie	Rek	Ludwig-Maximilians-Universität Munich, Germany
Trevor	Thompson	University of Greenwich, UK
Vasilios	Karageorgiou	University of Exeter, UK
Virginia	Chiocchia	University of Bern, Switzerland
Yikang	Zhu	Shanghai Jiao Tong University, China
Yukiko	Honda	Nagasaki University, Japan



# Living online systematic review and meta-ecological study




# Living online systematic review and meta-ecological study



# Pandemic of publications

Papers identified and screened since January 2020



Living Evidence on COVID-19


# Data extraction

- **Restricted study inclusion criteria to prioritise data extraction**
  - Longitudinal studies
  - Cross-sectional studies with more than 1000 participants
  - Studies that did not use social media to identify participants
- **Dichotomous and continuous outcomes**
  - Nr diagnosed, mean score on a symptoms scale
  - In the study population and subgroups by age and sex
- **Population characteristics** (comorbidities, % of COVID19 cases etc)
- **Risk of bias, design characteristics**
- **Timing of the study**



# First results

Data collected until March 2021



# Extract from data

Population	Condition	Scale	Sample Size	Score	SD	Country	Timepoint	Stringency	First Infection	Days in pandemic
Adults	Mental Wellbeing	WHO-5	2458	62	45	Denmark	31.03.20	72.22	27.02.20	33
Adults	Anxiety	GAD-7	5033	11	3.7	China	30.01.20	8.33	22.01.20	8

**Stringency index:** between 0 and 100 from Oxford Covid19 Gov Resp tracker

For each timepoint and country we map the stringency of the containment measure

**Time spent in the pandemic:** The time between study data collection and the timepoint of the first case in the respective country

# Some definitions...

- **Scaled outcome:** To synthesize mean scores of different symptoms scales for the same condition, we need to transform them according to their lower and maximum value
  - *Scaled score 0: No symptoms*
  - *Scaled score 1: Maximum score on symptoms scale*
- **Pandemic data:** those collected in China and HK after 1/1/2020 or after 1/3/2020 for the rest of the world

<b>All</b>	<b>164</b>
------------	------------

<b>Design</b>	
Pandemic data	129
Longitudinal studies	35

<b>Population</b>	<b>Number of studies</b>
Children	7
Adolescents	8
Adults	122
Elderly	20
Mixed	7

	<b>median</b>	<b>range</b>
Stringency Index	73	0 to 80
Time spent in the pandemic (days)	53	0 to 224

164 studies reporting on 49 different mental health outcomes

<b>Condition</b>	<b>Number of studies</b>
Depression	84
Anxiety	74
Depression & Anxiety	31
Sleep disturbance	18



# Filtering


## Condition

- ☒ Anxiety
- ☒ Anxiety 'OR' Depression
- ☒ Depression
- ☒ Depression and Anxiety
- ☒ General screening
- ☒ Mental Wellbeing
- ☒ PTSD
- ☒ Panic
- ☒ Psychological Distress
- ☒ Sleep disturbance


## Country

- ☒ Austria
- ☒ Canada
- ☒ China
- ☒ Hong Kong
- ☒ Italy
- ☒ Japan
- ☒ Spain
- ☒ United Kingdom
- ☒ United States
- ☒ Viet Nam


Country-Condition



Subgroup-Condition



## Prevalence vs Stringency



General screening (several conditions)

Sleep disturbance

Mental Wellbeing

# Depression

Alcohol/substance abuse


Post-traumatic stress disorder

## Depression and Anxiety

Suicidal thoughts or behaviour

# Anxiety

Quality of Life



subthreshold depression,  
minor depression, mild  
depressive symptoms not  
reaching clinical threshold

#### PHQ9 scores

0-4: no depression


5-9: mild depressive symptoms not  
reaching clinical threshold

10-14: mild major depression


15-19: moderate major depression

20+: severe major depression.






Smaller studies exaggerate the mean symptoms?




Differences in mean depression score men vs women by age group

**Total difference in PHQ9 between women and men:**  
1.27 (1.09; 1.49)




for **every 10 units increase in stringency index**,  
the mean symptoms **increase by 0.24** in  
PHQ9 scale


# Association difference between before and during the pandemic



Mean score from 10 studies between 2015-06-15 and 2020-06-15



Mean score from 10 studies between 2015-06-15 and 2020-06-15




# Next steps

- Data are changing as we integrate more studies (*about 130 in the pipeline*)
- The associations are observational
  - Need to account for possible confounders
  - Risk of bias and small study effects
- We need to account for pre-pandemic prevalence/symptoms score in each cross-sectional study
  - Identify pre-pandemic data to match the observed information
- **Challenge:** to keep updating the dataset and motivate the volunteers



# MHCovid on twitter

Account @MH\_COVID



*Please follow and re-tweet 😊*